Sequenom Says Competitors Will Have to License IP for Noninvasive T21 Detection Tests

A Sequenom official said that if another company "wanted to offer a trisomy 21 [laboratory-developed test], they would need to come through us" to license the technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.